Used in the treatment of metastatic castration-resistant prostate cancer, particularly in patients who have previously received docetaxel-based therapy. It functions by inhibiting microtubule depolymerization, leading to cell cycle arrest and apoptosis in cancer cells. Its ability to remain effective in docetaxel-resistant cases makes it a valuable option in advanced prostate cancer management. Administered intravenously, it is often combined with corticosteroids to reduce the risk of hypersensitivity reactions and fluid retention.